Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMYD3 | Q9H7B4 | 6/20 | 0.52 |
| ▸ | HPGDS | O60760 | 1/20 | 0.51 |
| ▸ | EGLN1 | Q9GZT9 | 8/20 | 0.46 |
| ▸ | KHK | P50053 | 1/20 | 0.44 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | KDM1A | O60341 | 1/20 | 0.41 |
| ▸ | DGAT2 | Q96PD7 | 1/20 | 0.41 |
| ▸ | PTK2 | Q05397 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2960453 | 0.77 | HDAC4 (0.47) | — | |
| SCHEMBL15760960 | 0.76 | SMYD3 (0.46) | SMYD3HPGDSEGLN1KDM1A | |
| Hydrochloric Acid SCHEMBL15757869 | 0.75 | SMYD3 (0.47) | SMYD3HPGDSEGLN1KDM1A | |
| SCHEMBL2964004 | 0.74 | SMYD3 (0.71) | SMYD3HPGDSKHK | |
| SCHEMBL16984657 | 0.73 | SMYD3 (0.54) | SMYD3HPGDSKDM1A | |
| SCHEMBL2957750 | 0.72 | SMYD3 (0.50) | SMYD3HPGDSKHK | |
| SCHEMBL17294425 | 0.71 | HCAR2 (0.43) | — | |
| SCHEMBL24897343 | 0.71 | SMYD3 (0.55) | SMYD3HPGDSEGLN1KHK | |
| SCHEMBL13575614 | 0.70 | SMYD3 (0.53) | SMYD3HPGDSKHKNPC1RAB9A | |
| SCHEMBL17294335 | 0.70 | ATM (0.47) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7772253-B2 | Amide derivatives as somatostatin receptor 5 antagonists | HOFFMAN-LA ROCHE INC. (US) | 2010-08-10 | — | — | US | disclosed |
| EP-1893603-B1 | PIPERIDIN-4-YL-AMIDE DERIVATIVES AND THEIR USE AS SST RECEPTOR SUBTYPE 5 ANTAGONISTS | HOFFMANN LA ROCHE (CH) | 2009-10-14 | — | — | EP | disclosed |
| EP-1893603-A1 | PIPERIDIN-4-YL-AMIDE DERIVATIVES AND THEIR USE AS SST RECEPTOR SUBTYPE 5 ANTAGONISTS | F. Hoffmann-La Roche AG (CH) | 2008-03-05 | — | — | EP | disclosed |
| WO-2006128803-A1 | PIPERIDIN-4-YL-AMIDE DERIVATIVES AND THEIR USE AS SST RECEPTOR SUBTYPE 5 ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2006-12-07 | — | — | WO | disclosed |
| US-20060276508-A1 | Amide derivatives as somatostatin receptor 5 antagonists | F. HOFFMANN-LA ROCHE AG (CH) | 2006-12-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060276508-A1 | Amide derivatives as somatostatin receptor 5 antagonists | SSTR5, SSTR3, SSTR1 | SMYD3 2731/4885HPGDS 2883/4885EGLN1 2137/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.